Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
Compugen is a drug discovery company with a unique, broadly applicable, predictive...
Compugen is a drug discovery company with a uni...
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
Myriad Genetics, Inc., is a leading precision medicine company dedicated to being ...
Myriad Genetics, Inc., is a leading precision m...
ContraFect is a clinical-stage biotechnology company focused on discovering and de...
ContraFect is a clinical-stage biotechnology co...
Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...
Sophiris Bio Inc. is a late-stage biopharmaceut...
Novartis is reimagining medicine to improve and extend peoples lives. As a leadin...
Novartis is reimagining medicine to improve and...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...
20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...
20/20 GeneSystems, Inc. an early stage digital ...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Join the National Investor Network and get the latest information with your interests in mind.